Jiri Drahota
Overview
Explore the profile of Jiri Drahota including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Potuznik P, Drahota J, Horakova D, Peterka M, Mazouchova A, Matyas D, et al.
J Cent Nerv Syst Dis
. 2024 Jul;
16:11795735241262743.
PMID: 39055049
Background: Cladribine, a selective immune reconstitution therapy, is approved for the treatment of adult patients with highly active multiple sclerosis (MS). Objectives: Provide experience with cladribine therapy in a real-world...
2.
Glaser A, Butzkueven H, van der Walt A, Gray O, Spelman T, Zhu C, et al.
J Neurol
. 2024 Apr;
271(6):3616-3624.
PMID: 38561543
Background: The Big Multiple Sclerosis Data (BMSD) network ( https://bigmsdata.org ) was initiated in 2014 and includes the national multiple sclerosis (MS) registries of the Czech Republic, Denmark, France, Italy,...
3.
Spelman T, Magyari M, Butzkueven H, van der Walt A, Vukusic S, Trojano M, et al.
Front Neurol
. 2024 Jan;
14:1274194.
PMID: 38187157
Background: Treatment switching is a common challenge and opportunity in real-world clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated interest in the identification of reliable and robust predictors...
4.
Stastna D, Elberling F, Pontieri L, Framke E, Horakova D, Drahota J, et al.
Eur J Neurol
. 2023 Nov;
31(3):e16163.
PMID: 38015454
Background And Purpose: We evaluated whether there was a difference in the occurrence of relapses pre- and post-COVID-19 vaccination in a nationwide cohort of Danish patients with relapsing multiple sclerosis....
5.
Nicholas R, Rodgers J, Witts J, Lerede A, Friede T, Hillert J, et al.
Ther Adv Neurol Disord
. 2023 Sep;
16:17562864231198963.
PMID: 37771841
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing-remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising...
6.
Hradilek P, Zapletalova O, Hanulikova P, Kubala Havrdova E, Woznicova I, Mazouchova A, et al.
Mult Scler Relat Disord
. 2023 Jun;
76:104790.
PMID: 37348317
Introduction: The influence of breastfeeding and it´s duration on the course of multiple sclerosis (MS) is unclear. Here we analyzed a real-world data for breastfeeding women with MS and their...
7.
Hrnciarova T, Drahota J, Spelman T, Hillert J, Lycke J, Kubala Havrdova E, et al.
Mult Scler Relat Disord
. 2023 Jun;
76:104803.
PMID: 37329786
Background: In relapsing-remitting multiple sclerosis (RRMS) the most common treatment strategy has been to start with low-moderate efficacy disease modifying therapy (LE-DMT) and to escalate to more efficacious treatments in...
8.
Stastna D, Drahota J, Lauer M, Mazouchova A, Menkyova I, Adamkova J, et al.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
. 2023 Apr;
168(3):262-270.
PMID: 37114703
Aims: Multiple sclerosis treatment strategies are changing in the Czech Republic. According to data from 2013-2021, the proportion of patients starting high-efficacy disease-modifying therapies is increasing. In this survey, we...
9.
Forsberg L, Spelman T, Klyve P, Manouchehrinia A, Ramanujam R, Mouresan E, et al.
Mult Scler J Exp Transl Clin
. 2023 Feb;
9(1):20552173231153557.
PMID: 36816812
Background: To assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease...
10.
Stastna D, Menkyova I, Drahota J, Hrnciarova T, Kubala Havrdova E, Vachova M, et al.
Mult Scler Relat Disord
. 2023 Feb;
70:104549.
PMID: 36796224
No abstract available.